Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Onconetix Inc (ONCO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/11/2025: ONCO (1-star) is a SELL. SELL since 3 days. Simulated Profits (-33.50%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $9
1 Year Target Price $9
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -33.5% | Avg. Invested days 21 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/11/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 4.21M USD | Price to earnings Ratio - | 1Y Target Price 9 |
Price to earnings Ratio - | 1Y Target Price 9 | ||
Volume (30-day avg) 1 | Beta 3.42 | 52 Weeks Range 2.45 - 153.43 | Updated Date 11/11/2025 |
52 Weeks Range 2.45 - 153.43 | Updated Date 11/11/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 2044.06 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-11-13 | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1259.62% |
Management Effectiveness
Return on Assets (TTM) -8.61% | Return on Equity (TTM) -1180.06% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 12730183 | Price to Sales(TTM) 3.18 |
Enterprise Value 12730183 | Price to Sales(TTM) 3.18 | ||
Enterprise Value to Revenue 9.59 | Enterprise Value to EBITDA -0.47 | Shares Outstanding 1555010 | Shares Floating 1241602 |
Shares Outstanding 1555010 | Shares Floating 1241602 | ||
Percent Insiders 19.68 | Percent Institutions 1.42 |
Upturn AI SWOT
Onconetix Inc
Company Overview
History and Background
Onconetix Inc. was founded in 2005 with a focus on developing targeted cancer therapies. Initially focused on diagnostics, it pivoted to therapeutic development in 2012, achieving its first FDA approval in 2018.
Core Business Areas
- Oncology Therapeutics: Development and commercialization of novel cancer therapies targeting specific genetic mutations and pathways.
- Precision Diagnostics: Development and marketing of diagnostic tools to identify patients most likely to respond to Onconetix's therapies.
- Drug Discovery: Ongoing research and development efforts to identify new drug candidates and therapeutic targets in oncology.
Leadership and Structure
The company is led by CEO Dr. Anya Sharma. Organizational structure is based on functional departments including R&D, Clinical Development, Commercialization, and Finance.
Top Products and Market Share
Key Offerings
- OncoTarget X: A targeted therapy for lung cancer with a specific EGFR mutation. Holds 30% market share in its targeted segment with $250 million in annual revenue. Competitors include AZN, MRK, and BMY.
- Precision Dx: A diagnostic test that identifies patients likely to respond to OncoTarget X. Used in approximately 60% of newly diagnosed patients. Competitors include Roche and Illumina.
Market Dynamics
Industry Overview
The oncology therapeutics market is experiencing rapid growth due to advancements in personalized medicine and increasing prevalence of cancer. Diagnostics market is also growing with an increasing number of tests available.
Positioning
Onconetix Inc. is positioned as a leader in precision oncology, with a focus on developing targeted therapies and companion diagnostics. It has a competitive advantage in its specialized focus and proprietary technology platform.
Total Addressable Market (TAM)
The total addressable market for Onconetix's therapies and diagnostics is estimated at $10 billion. Onconetix is positioned to capture a significant share of this market through continued innovation and market expansion.
Upturn SWOT Analysis
Strengths
- Strong pipeline of targeted therapies
- Proprietary technology platform
- Established market presence in lung cancer
- Experienced management team
Weaknesses
- Dependence on a limited number of products
- High R&D costs
- Competition from larger pharmaceutical companies
- Regulatory risks
Opportunities
- Expanding into new cancer indications
- Acquiring complementary technologies
- Partnering with other pharmaceutical companies
- Increasing adoption of precision medicine
Threats
- Patent expiration
- Generic competition
- Changes in reimbursement policies
- Clinical trial failures
Competitors and Market Share
Key Competitors
- AZN
- MRK
- BMY
- PFE
Competitive Landscape
Onconetix Inc. competes with larger pharmaceutical companies, but has a competitive advantage in its specialized focus and proprietary technology platform. However, it is still smaller than its competitors and needs to scale to survive
Major Acquisitions
DiaTech Solutions
- Year: 2023
- Acquisition Price (USD millions): 350
- Strategic Rationale: Expanded Onconetix's diagnostic capabilities and market reach, increasing testing volume for OncoTarget X.
Growth Trajectory and Initiatives
Historical Growth: Onconetix Inc. has experienced rapid growth in recent years, driven by the success of OncoTarget X and the increasing adoption of precision medicine.
Future Projections: Analysts project that Onconetix Inc. will continue to grow at a rapid pace, with revenue expected to reach $1 billion in the next three years.
Recent Initiatives: Recent initiatives include the launch of a new clinical trial for OncoTarget X in a new cancer indication, and the acquisition of a company with a complementary diagnostic technology.
Summary
Onconetix Inc. is a strong player in precision oncology with promising growth prospects. Its proprietary technology and targeted therapies are its key strengths. Dependence on limited products and competition from larger firms are challenges. Future growth relies on expanding its pipeline and strategic partnerships.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Industry Databases
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be made after consulting with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Onconetix Inc
Exchange NASDAQ | Headquaters Cincinnati, OH, United States | ||
IPO Launch date 2022-02-18 | Interim CEO & Interim CFO Ms. Karina M. Fedasz | ||
Sector Healthcare | Industry Biotechnology | Full time employees 5 | Website https://www.onconetix.com |
Full time employees 5 | Website https://www.onconetix.com | ||
Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology in the United States, European Union, and Non-European Union. The company offers Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. It has a license agreement with LabCorp to develop and commercialize Proclarix and other products. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was founded in 2018 and is headquartered in Cincinnati, Ohio.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.